Pancreatic Cancer

RFS 2000 Shows 63 percent Response or Stable Disease in Patients

Published in Cancer Weekly, June 8th, 1998

SuperGen, Inc., San Ramon, California, announced updated interim results from an ongoing Phase II trial of its proprietary drug RFS 2000 for the treatment of pancreatic cancer.

RFS 2000 is a second-generation topoisomerase I inhibitor, which causes single-strand breaks in DNA. Median survival to date is 16.2 months among responders, which is the longest survival rate ever reported among pancreatic cancer patients.

Among stable patients, median survival was 9.7 months and among non-responders, 5.9 months. Data shows that among 61 evaluable patients, 33 percent were responders, 30 percent were stable and 37 percent were non-responders following...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1998-06-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry